A biotech with forward earnings priced at 8.6x, a PEG below 0.7, and free cash flow converting at 171% of net income is a quality business at an undemanding multiple — yet three consecutive earnings misses and a death cross technical hard block are actively working against that thesis, leaving the risk/reward favorable in theory at 6.5-to-1 but blocked in practice.
Thesis pillars
- Quality Valuation Cash Conversion↓Deteriorating
- Consecutive Earnings Execution Failures↓Deteriorating
- Death Cross Momentum Hard Block↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. At $67.36, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Sanofi; Concentration risk — Supplier: sole source raw material suppliers.
BioMarin Pharmaceutical develops and commercializes medicines for rare genetic diseases, with eight approved commercial therapies generating $3.2 billion in 2025 revenues. Products span achondroplasia (VOXZOGO, $927M), mucopolysaccharidosis (VIMIZIM, NAGLAZYME, ALDURAZYME), PKU... Read more
Sell if holding. At $67.36, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Sanofi; Concentration risk — Supplier: sole source raw material suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, news boost analyst 0.80, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical's eight commercial therapies generated $3.2 billion in total revenues in 2025, with VOXZOGO (vosoritide for achondroplasia) at $926.9 million and VIMIZIM (elosulfase alpha for MPS IVA) at $792.1 million as the two largest contributors. ALDURAZYME for MPS I is commercialized exclusively by Sanofi globally, while all other products are marketed directly in the U.S., Europe, South America, and other significant markets. In December 2025, BioMarin signed a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction expected to close in the second quarter of 2026.
Revenue comes from rare-disease therapies sold through specialty pharmacies, hospitals, non-U.S. government agencies, and distributors. During 2025, three customers generated 37% of net product revenue, and Sanofi is the sole global customer for ALDURAZYME, purchasing all supply from BioMarin in exchange for royalties of 39.5% to 50% of worldwide net sales depending on volume. API for VOXZOGO, NAGLAZYME, PALYNZIQ, and ALDURAZYME is manufactured in-house at Novato, California; API for BRINEURA and VIMIZIM comes from Shanbally, Cork, Ireland, a facility that received EU drug product filling approval in 2024. PALYNZIQ and KUVAN API are sourced from third-party contract manufacturers. Generic versions of KUVAN have entered the U.S. and EU markets, continuing to erode KUVAN revenues. BioMarin's pipeline includes a pivotal Phase 3 VOXZOGO study in hypochondroplasia and Phase 1/2 data for BMN 351 in Duchenne Muscular Dystrophy showing 5.0% mean absolute dystrophin expression at week 25 in the 9 mg/kg cohort.
Show full overview
BioMarin's manufacturing relies on both in-house facilities and third-party contract manufacturers, and in certain instances there is only one approved contract manufacturer for specific aspects of the process. Similarly, certain raw materials are available from only a sole-source supplier—designated as the only recognized supply source with no alternative. A disruption at any sole-source supplier or single-approved contract manufacturer could delay product availability for ultra-rare diseases where patients have no therapeutic substitute and where regulatory re-qualification of backup suppliers is a lengthy, inspection-dependent process. The company mitigates this through safety stock and supply agreements but acknowledges future supply continuity cannot be guaranteed.
See also: Healthcare · Biotechnology
From BioMarin Pharmaceutical Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-08-16Recent Developments — BioMarin Pharmaceutical Inc.
Latest news
- NEWS H.C. Wainwright reiterates BioMarin stock rating at Neutral - Investing.com — Investing.com neutral
- NEWS BMRN|BioMarin Pharmaceutical Inc|Price:60.313|Chg%:-1.057 - TradingKey — TradingKey negative
- NEWS BMRN|BioMarin Pharmaceutical Inc|Price:60.313|Chg%:-1.057 - tradingkey.com — tradingkey.com neutral
- NEWS BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Monday - MarketBeat — MarketBeat neutral
- NEWS Earnings Preview: BMRN to Report Financial Results Post-market on May 04 - Moomoo — Moomoo neutral
Generated 2026-08-16T12:32:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerthree customers37%10-K Item 1: 'During 2025, 37% of our net product revenue was generated by three customers.'
- HIGHCustomerSanofi10-K Item 1: 'Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties.'
- MEDIUMProductVOXZOGO10-K Item 1: 'VOXZOGO (vosoritide)| | Achondroplasia| | $| 926.9 ... $3.2 billion in total revenues'
- HIGHSuppliersole source raw material suppliers10-K Item 1: 'available in some instances from one supplier ... sole source (the only recognized supply source available to us)'
- HIGHSuppliersingle approved contract manufacturer10-K Item 1: 'In certain instances, there is only one approved contract manufacturer for certain aspects of the manufacturing process.'
Material Events(8-K, last 90d)
- 2026-06-04Item 5.02LOWBioMarin's 2026 Annual Meeting on June 2, 2026 approved amendment to 2017 Equity Incentive Plan increasing shares reserved by 7,650,000. Routine compensatory arrangement approval; no personnel departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $67.36, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: Sanofi; Concentration risk — Supplier: sole source raw material suppliers. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Prior stop was $62.84. Score 5.5/10, moderate confidence.
Take-profit target: $81.50 (+21.0% upside). Prior stop was $62.84. Stop-loss: $62.84.
Concentration risk — Customer: Sanofi; Concentration risk — Supplier: sole source raw material suppliers; Consecutive earnings misses (3).
BioMarin Pharmaceutical Inc. trades at a P/E of 182.1 (forward 10.2). TrendMatrix value score: 6.3/10. Verdict: Sell.
33 analysts cover BMRN with a consensus score of 4.1/5. Average price target: $91.
What does BioMarin Pharmaceutical Inc. do?BioMarin Pharmaceutical develops and commercializes medicines for rare genetic diseases, with eight approved commercial...
BioMarin Pharmaceutical develops and commercializes medicines for rare genetic diseases, with eight approved commercial therapies generating $3.2 billion in 2025 revenues. Products span achondroplasia (VOXZOGO, $927M), mucopolysaccharidosis (VIMIZIM, NAGLAZYME, ALDURAZYME), PKU (PALYNZIQ, KUVAN), and other rare conditions, sold globally through specialty pharmacies, hospitals, and—for ALDURAZYME—exclusively through Sanofi.